What should oncology nurses and advanced practice providers understand about GLP-1 RAs in the care of patients with breast ...

Samantha Shenoy, NP, MSN, provides nursing guidance on teclistamab/subcutaneous daratumumab’s second-line approval in multiple myeloma. On March 5, the FDA approved the combination of teclistamab ...

Having dealt with difficult-to-diagnose breast cancer herself, Patricia Jakel, MN, RN, AOCN, is all too familiar with the need for vigilant monitoring, even when that goes beyond what is recommended.

Data show that sentinel lymph node biopsy is becoming less routine for older women with breast early stage HR-positive, HER2-negative breast cancer.

The FDA has approved teclistamab (Tecvayli) daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of ...

Antonio Ocejo, MD, discusses supportive care implications from new data comparing ipilimumab/nivolumab in older vs younger ...

A real-world study found rates of toxicity-related T-DXd discontinuation in HER2-low metastatic breast cancer similar to those observed in DESTINY-Breast04. A real-world cohort of patients with ...

A significant portion of patients with locally advanced breast cancer receiving ultra-hypofractionation radiotherapy responded to treatment. Ultra-hypofractionated radiotherapy showed signs of ...

Antonio Ocejo, MD, discusses supportive care implications from new data comparing ipilimumab/nivolumab in older vs younger age groups with mccRCC.

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...